Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis

J. Sarin, S. S. DeRossi, S. O. Akintoye

Research output: Contribution to journalReview articlepeer-review

97 Scopus citations


Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia®) and zoledronic acid (Zometa®), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.

Original languageEnglish (US)
Pages (from-to)277-285
Number of pages9
JournalOral Diseases
Issue number3
StatePublished - Apr 2008
Externally publishedYes


  • Biology
  • Bisphosphonates
  • Bone marrow
  • Jaw
  • Osteonecrosis

ASJC Scopus subject areas

  • Otorhinolaryngology
  • General Dentistry


Dive into the research topics of 'Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis'. Together they form a unique fingerprint.

Cite this